Therefore, future studies incorporating expression analyses of key markers such as LC3B, p62, and p-MLKL may help elucidate TIG3′s potential role in regulating these non-canonical cell death pathways, ultimately enhancing our understanding of its anti-tumor mechanisms. The gene discussed is MAP1LC3B; the disease is neoplasm.